A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DAPSA / Disease Activity Index for PsA

[Related PubMed/MEDLINE]
Total Number of Papers: 27
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DAPSA  (>> Co-occurring Abbreviation)
Long Form:   Disease Activity Index for PsA
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab. AUROC, BMI, LEI, LR, ML, PsA, SEC, XGBoost
2022 Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. AS, axPsA, BASDAI, CRP, HAQ-DI, IGA, IL, MRI, PsA, SI, SPARCC
2022 Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. CDSR, MDA, PASI, PsA, VLDA
2022 Validity and psychometric characteristics of the self-administered comorbidity questionnaire in patients with psoriatic arthritis. BASDAI, BMI, HAQ, PASI, PsA, PsAQoL, SCQ, SF-36
2021 Clinical Characteristics of Psoriatic Arthritis in Chinese Patients: A Cross-Sectional Study. PASI, PsA
2021 Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. CPDAI, GRAPPA, mCPDAI, MDA, mGRACE, PASDAS, PsA, SRMs
2021 Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. CPDAI, GRAPPA, mCPDAI, MDA, mGRACE, PASDAS, PsA, SRMs
2021 Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors. DAS28-CRP, EULAR, HAQ-DI, IXE, MDA, PBO, TNFi
2021 Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides? CS, CSI, HAQ-DI, PsA, RA
10  2021 Real-life efficacy of guselkumab in patients with early psoriatic arthritis. PtGA
11  2020 Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. LDA, PsA
12  2020 Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps. CPDAI, DAS, GRAPPA, PsA
13  2020 Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. DEGs, PsA, TNFi
14  2020 Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose? LDA, PASDAS, sDAPDA-LDA, sMDA, sPASDAS-LDA
15  2019 Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. HRs, LDA, MDA
16  2019 Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. CV, PsA, SCORE, US
17  2019 Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes? HRs, MDA, PsA, RA, SpA
18  2019 Residual Disease Activity and Associated Factors in Psoriatic Arthritis. BSA, CASPAR, LDA, MDA, PASI, PsA, RDA, VAS, VLDA
19  2018 Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis. DAPSA-LDA, HAQ, MDA, PsA, SF-36 BP
20  2018 Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. LDA, MDA, PsA, SJC, TJC, VLDA
21  2018 Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. ---
22  2018 Effectiveness and safety of ustekinumab in naive or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. CRP, ESR, HAQ-S, LEI, MDA, PASI, PsA, VASp
23  2018 Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. AEs, cDMARD, cDMARDs, MDA, PsA, TNFi
24  2018 Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. ---
25  2018 What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis? cDAPSA, DMARD, PASDAS, PsA, TICOPA, VLDA
26  2017 Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. PASDAS, PsA
27  2014 Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. ESR, PASDAS, PASI, PsA, WBC